CoChat

The DOI matches its Crossref record; 136 of the 137 references it cites were found in a registry or an index; 46 of the 120 sources its claims cite were checked for support.

An Updated Review on the Metabolite (AM404)-Mediated Central Mechanism of Action of Paracetamol (Acetaminophen): Experimental Evidence and Potential Clinical Impact

Open access
Mallet, Christophe, Desmeules, Jules, Pegahi, Rassa, Eschalier, Alain · 2023 · Journal of Pain Research

Abstract

Paracetamol remains the recommended first-line option for mild-to-moderate acute pain in general population and particularly in vulnerable populations. Despite its wide use, debate exists regarding the analgesic mechanism of action (MoA) of paracetamol. A growing body of evidence challenged the notion that paracetamol exerts its analgesic effect through cyclooxygenase (COX)-dependent inhibitory effect. It is now more evident that paracetamol analgesia has multiple pathways and is mediated by the formation of the bioactive AM404 metabolite in the central nervous system (CNS). AM404 is a potent activator of TRPV 1 , a major contributor to neuronal response to pain in the brain and dorsal horn. In the periaqueductal grey, the bioactive metabolite AM404 activated the TRPV 1 channel‐mGlu5 receptor‐PLC‐DAGL‐CB1 receptor signaling cascade. The present article provides a comprehensive literature review of the centrally located, COX-independent, analgesic MoA of paracetamol and relates how the current experimental evidence can be translated into clinical practice. The evidence discussed in this review established paracetamol as a central, COX-independent, antinociceptive medication that has a distinct MoA from non-steroidal anti-inflammatory drugs (NSAIDs) and a more tolerable safety profile. With the establishment of the central MoA of paracetamol, we believe that paracetamol remains the preferred first-line option for mild-to-moderate acute pain for healthy adults, children, and patients with health concerns. However, safety concerns remain with the high dose of paracetamol due to the NAPQI-mediated liver necrosis. Centrally acting paracetamol/ p -aminophenol derivatives could potentiate the analgesic effect of paracetamol without increasing the risk of hepatoxicity. Moreover, the specific central MoA of paracetamol allows its combination with other analgesics, including NSAIDs, with a different MoA. Future experiments to better explain the central actions of paracetamol could pave the way for discovering new central analgesics with a better benefit-to-risk ratio. Keywords: paracetamol, acetaminophen, AM404, analgesia, molecular targets

Overview

CoChat Summary

TL;DR

This review argues that paracetamol analgesia is centrally mediated by its AM404 metabolite and is largely COX-independent, involving TRPV1, CB1, Cav3.2, and serotonergic pathways. It concludes that paracetamol remains a first-line option for mild-to-moderate acute pain and that centrally acting paracetamol analogs may improve analgesia without NAPQI-mediated hepatotoxicity.

Key findings

  • Paracetamol is converted centrally to the bioactive metabolite AM404: after hepatic deacetylation to p-aminophenol, FAAH converts it to AM404 in the brain. The first human evidence detected AM404 in cerebrospinal fluid in 17 of 26 patients who received 1 g paracetamol.
  • AM404 activates TRPV1 and, in the periaqueductal grey, the TRPV1 channel–mGlu5 receptor–PLC–DAGL–CB1 receptor signaling cascade; Cav3.2 T-type calcium channels act mainly supraspinally and downstream of TRPV1, and serotonergic pathways also contribute.
  • The analgesic mechanism is described as COX-independent: paracetamol’s antinociceptive profile differs from ibuprofen, COX-3 is unlikely to be clinically relevant in humans, and COX inhibition is more closely related to hypothermic/antipyretic effects.
  • Clinically, paracetamol is presented as first-line for mild-to-moderate acute pain in healthy adults, children, and patients with health concerns; the maximum recommended dose is 1 g every 4–6 hours up to 4 g/day, while hepatotoxicity from NAPQI remains a major safety issue.

Methods

  • Narrative literature review: Medline via PubMed was searched from inception to May 2022 using the keywords (paracetamol[MeSH Terms]) OR (acetaminophen[MeSH Terms])) AND (AM404), complemented by manual screening of relevant references.
  • Evidence was synthesized narratively from experimental animal studies, human cerebrospinal fluid and genetic studies, clinical trials, and a table of selected randomized trials of paracetamol plus opioids for acute postoperative pain.
  • No systematic review, meta-analysis, or formal quantitative synthesis was reported.

Limitations

  • The paper states that evidence for the morphine-sparing effect of paracetamol/opioid combinations is limited and further studies are needed; the exact nature of the spinal tropisetron-sensitive receptor involved remains to be elucidated; and how CB1 receptors are involved requires further study.
  • The paper states that safety issues remain controversial or inconclusive, including hepatotoxicity, and that some combination safety signals—such as hemoglobin decreases with longer-term paracetamol/ibuprofen and upper GI events with NSAID plus acetaminophen—warrant further research.
  • Evident from the text: as a narrative review, it does not report a systematic search beyond PubMed and the AM404 keyword strategy, nor a formal quality/risk-of-bias assessment or quantitative synthesis, so clinical recommendations rest on selected evidence.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.2147/jpr.s393809

Cites

136 of 136 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Schematic representation of the central mechanism of action of paracetamol to its antinociceptive activity. Paracetamol is deacetylated in p-aminophenol in the liver, then metabolized in the brain by FAAH into AM404. AM404 activates the TRPV1 channel‐mGlu5 receptor‐PLC‐DAGL‐CB1 pathway and co-activates the Cav 3.2 T-type calcium channel, which in turn reinforces the activity of the descending serotonergic pathways.
Figure 1 Schematic representation of the central mechanism of action of paracetamol to its antinociceptive activity. Paracetamol is deacetylated in p-aminophenol in the liver, then metabolized in the brain by FAAH into AM404. AM404 activates the TRPV1 channel‐mGlu5 receptor‐PLC‐DAGL‐CB1 pathway and co-activates the Cav 3.2 T-type calcium channel, which in turn reinforces the activity of the descending serotonergic pathways.CC BY-NC · PubMed Central

Verification

Claims the paper makes

34 Valid · 3 Not valid · 35 Not checked · 34 Own results and interpretations

56 more claims · 12 with their cited sources checked

Create a free account to see all 106 claims and to verify the 12 references still open.

See all claims — free account
  • It may state two separate claims as one. 33
  • Probably not a substantial claim. 14

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

4 of 4

Citations

Cites

Research works printed but not linked: 4

  1. Boutaud, 2002, Proc Natl Acad Sci U S A, 99, 7130, 10.1073/PNAS.102588199/ASSET/682AB754-3CF6-4EC9-B4FB-18483C903C21/ASSETS/GRAPHIC/PQ1025881008.JPEG · doi:10.1073/pnas.102588199/asset/682ab754-3cf6-4ec9-b4fb-18483c903c21/assets/graphic/pq1025881008.jpeg
  2. Jozwiak-Bebenista, 2014, Acta Pol Pharm Drug Res, 71, 11
  3. Evke, 2022, Genes, 13, 10.3390/GENES13030421/S1 · doi:10.3390/genes13030421/s1
  4. Schug, 2006, Clin Rheumatol, 25, 16, 10.1007/S10067-006-0202-9/FIGURES/5 · doi:10.1007/s10067-006-0202-9/figures/5

Cited by

See all 83

Metadata

Authors
Mallet, C., Desmeules, J., Pegahi, R., & Eschalier, A.
Affiliations
  • Inserm (FR)
  • University of Geneva (CH)
Corresponding author
Eschalier, Alain
Venue
Journal of Pain Research
Published
2023-03
Volume
Volume 16
Pages
1081-1094
ISSN
1178-7090 (ISSN-L)
OpenAlex
W4361217917
Cited by
83
References
137
Citations by year
2026: 22 · 2025: 33 · 2024: 17 · 2023: 11
FWCI
2.95
Type
journal article
Language
en
Open access
Locations
  • Journal of Pain Research (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, cc-by-nc)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
  • Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
  • Life Sciences › Neuroscience › Sensory Systems › Ion Channels and Receptors
Keywords
paracetamol, analgesic mechanism, TRPV1, periaqueductal gray, mGlu5 receptor, central analgesia, acute pain, NSAID combination therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.